From: Targeting and sensitizing MDR cancer by an MMP2 and pH dual-responsive ZnO-based nanomedicine
Name | Particle size (nm) | PDI | Zeta potential (mV) | Drug loading (%) |
---|---|---|---|---|
ZnO | 56.43 ± 12.05 | 0.17 ± 0.06 | 24.22 ± 1.32 | – |
ZnO/DOX | 57.30 ± 9.23 | 0.16 ± 0.02 | 21.40 ± 1.89 | 16.28 |
DPPG | 343.77 ± 8.04 | 0.27 ± 0.01 | − 59.94 ± 3.20 | – |
ZnO/DPPG | 47.05 ± 3.29 | 0.22 ± 0.01 | − 45.30 ± 1.90 | – |
ZnO/DPPG/PEG-PE | 60.46 ± 6.12 | 0.13 ± 0.02 | − 16.98 ± 1.51 | – |
ZnO/DPPG/PEG-pp-PE | 73.11 ± 10.76 | 0.20 ± 0.01 | − 19.16 ± 3.03 | – |
ZnO/DPPG/PEG-PE/DOX | 60.11 ± 4.43 | 0.19 ± 0.03 | − 25.33 ± 0.54 | 10.33 |
ZnO/DPPG/PEG-pp-PE/DOX | 83.25 ± 20.87 | 0.20 ± 0.02 | − 20.43 ± 1.06 | 11.49 |